Program Moderator
Stephen B. Baylin, MD
Chief, Cancer Biology Division
The Johns Hopkins Oncology Center
Professor of Medicine and Oncology
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Program Faculty
Guillermo Garcia-Manero, MD
Associate Professor and Associate Internist
Department of Leukemia
Division of Cancer Medicine
University of Texas–MD Anderson Cancer Center
Houston, Texas
Steven D. Gore, MD
Associate Professor of Oncology
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Steven Grant, MD
Professor of Medicine, Biochemistry, and Pharmacology
Medical College of Virginia
Virginia Commonwealth University
Richmond, Virginia
Allen S. Yang, MD, PhD
Assistant Professor of Medicine
Division of Hematology
Keck School of Medicine
University of Southern California
Los Angeles, California
Release date: August 31, 2007
Expiration date: August 31, 2008
Expired
The content of this continuing medical education (CME) activity is derived from a symposium, “The Promise of Epigenetic Therapy,” presented at the 48th Annual Meeting of the American Society of Hematology.
Program Overview
The content of this continuing medical education (CME) activity is derived from a symposium, “The Promise of Epigenetic Therapy,” presented at the 48th Annual Meeting of the American Society of Hematology. This activity is offered in two formats: a print monograph and digital real-time symposium presentations.
Target Audience
This activity is intended for hematologists and oncologists.
Learning Objectives
At the conclusion of this continuing medical education (CME) activity, participants should be able to:
• Explain the role of DNA demethylation inhibitors in regulating gene expression in both healthy and cancerous states
• Describe the epigenetic and nonepigenetic mechanisms by which HDAC inhibitors kill hematologic and nonhematologic tumor cells
• Design a treatment strategy that exploits the complementary effects of DNA methylation inhibitors and HDAC inhibitors when used in combination
• Forecast the potential changes in cancer chemotherapy and chemoprevention that translational therapies may make possible
Accreditation Statement
Current Therapeutics Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide CME for physicians. Current Therapeutics Inc. takes responsibility for the content, quality, and scientific integrity of this CME activity.
Designation of Credit Statement
Current Therapeutics Inc. designates this CME activity for a maximum of 2 AMA PRA Category 1 Credits(TM). Each individual should claim only those hours of credit that he or she spent on the activity.
Faculty Disclosure
As a sponsor accredited by the ACCME, it is the policy of Current Therapeutics Inc. to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:
Dr. Baylin has disclosed receipt of research support from BioNumerick Pharmaceuticals, Department of Defense, National Institute of Environmental Health Sciences, National Institutes of Health/National Cancer Institute, OncoMethylome Sciences, and the
Susan G. Komen Breast Cancer Foundation.
Dr. Garcia-Manero has disclosed receipt of grant, research support, and honoraria from MGI Pharma and Pharmion.
Dr. Gore has disclosed consultant services for Celgene and Pharmion.
Dr. Grant has disclosed receipt of grant and research support from the Department of Defense and the National Institutes of Health.
Dr. Yang has disclosed receipt of grant and research support from Methylgene and consultant services for MGI Pharma and Pharmion.
Disclaimer
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
Privacy & Confidentiality Statement
Carden Jennings Publishing Co., Ltd., the publisher of Bloodline, does not collect or track personal information from participants in this CME activity. Generic information from server logs may be used to track and analyze the number of visits to the site, and to find out what types of browser software are used by visitors. This information will be used only in aggregate form, and used solely for improving website design and performance.
Click the “Start Activity” button to indicate you have reviewed the CME information for this activity.